Biosims Drive Down Roche Sales in Europe

Oct 20, 2017


Roche Holding’s top-selling drug, Rituxan, saw sales drop in Europe last quarter, amid competition from biosimilars.

First approved in 1997 and now a mainstay of treatment for blood cancers and some autoimmune diseases, Rituxan is the first major cancer treatment to have become vulnerable to competition from biosimilars in Europe.

The European Commission approved Celltrion’s rituximab biosimilar, Truxima, in February. In June, the EC approved Sandoz’s Rixathon. The U.S. FDA is currently reviewing an application by Celltrion and Israel’s Teva Pharmaceuticals.

Roche is relying on new drugs -- such as multiple sclerosis therapy, Ocrevus -- to drive sales as Herceptin and Avastin also face competition from biosimilars.

Read the Bloomberg article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments